Research Article

Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases with Osler-Weber- Rendu Syndrome

Volume: 3 Number: 3 December 20, 2020
European Journal of Rhinology and Allergy Cover
European Journal of Rhinology and Allergy
PDF Download

Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases with Osler-Weber- Rendu Syndrome

Abstract

Objective: This study presents the experience in epistaxis management in cases with Osler-Weber-Rendu syndrome (OWRS) and the outcomes of intravenous bevacizumab treatment in selected cases. Material and methods: The records of patients diagnosed with OWRS who underwent medical and/or surgical treatment in the Otorhinolaryngology department of İzmir Katip Çelebi University Atatürk Training and Research Hospital between 2004 and 2018 were retrospectively reviewed. Consequently, 10 patients diagnosed with OWRS according to Curaçao’s criteria were included in the study. Results: The mean epistaxis severity score (ESS) of the patients were 5.42±1.07 and 3.86±0.89 at first admission and after 3 months of follow-up, respectively. Moreover, four patients (40%) were evaluated for intravenous bevacizumab treatment after the initial treatment and/or surgery. Three patients underwent a high dose (5 mg/kg every 2 weeks for six times) of bevacizumab treatment, whereas one patient underwent a low dose (0.125 mg/kg every 2 weeks for six times) followed by a high dose of bevacizumab treatment. A decrease in ESS was observed in all cases after the treatment. Conclusion: Bevacizumab may be a promising agent for patients with refractory epistaxis. Currently, it is not approved for the treatment of Osler-Weber-Rendu syndrome and a multidisciplinary approach can be considered for off-label use.

Keywords

References

  1. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-7.
  2. Kühnel T, Wirsching K, Wohlgemuth W, Chavan A, Evert K, Vielsmeier V. Hereditary hemorrhagic telangiectasia. Otolaryngol Clin North Am 2018; 51: 237-54.
  3. Palmer BF, Clegg DJ. Oxygen sensing and metabolic homeostasis. Mol Cell Endocrinol 2014; 397: 51-8.
  4. Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120: 838-43.
  5. Robard L, Michel J, Prulière Escabasse V, Bequignon E, Vérillaud B, Malard O, et al. Guidelines of the French Society of Otorhinolaryngology (SFORL) (short version). Specific treatment of epistaxis in Rendu-Osler-Weber disease. Eur Ann Otorhinolaryngol Head Neck Dis 2017; 134: 37-41.
  6. Sharathkumar AA, Shapiro A. Hereditary hemorrhagic telangiectasia. Haemophilia 2008; 14: 1269-80.
  7. Zarrabeitia R, Albinana V, Salcedo M, Senaris-Gonzalez B, Fernandez-Forcelle-do J-L. A review on clinical management and pharmacological therapy on hereditary hemorrhagic telangiectasia (HHT). Curr Vasc Pharmacol 2010; 8: 473-81.
  8. Gaillard S, Dupuis-Girod S, Boutitie F, Rivière S, Morinière S, Hatron P-Y, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: A European cross-over controlled trial in a rare disease. J Thromb Haemost 2014; 12: 1494-502.

Details

Primary Language

English

Subjects

Otorhinolaryngology

Journal Section

Research Article

Authors

Kamran Hasanlı This is me
0000-0002-7187-6793
Türkiye

Publication Date

December 20, 2020

Submission Date

October 1, 2020

Acceptance Date

December 3, 2020

Published in Issue

Year 2020 Volume: 3 Number: 3

DOI

https://doi.org/10.5152/ejra.2020.328

IZ

https://izlik.org/JA26MS64FB

Cite

RIS / Bibtex
APA
Eren, E., Balcı, M. K., İşlek, A., Solmaz, Ş., & Hasanlı, K. (2020). Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases with Osler-Weber- Rendu Syndrome. European Journal of Rhinology and Allergy, 3(3), 69-71. https://doi.org/10.5152/ejra.2020.328
AMA
1.Eren E, Balcı MK, İşlek A, Solmaz Ş, Hasanlı K. Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases with Osler-Weber- Rendu Syndrome. Eur J Rhinol Allergy. 2020;3(3):69-71. doi:10.5152/ejra.2020.328
Chicago
Eren, Erdem, Mustafa Koray Balcı, Akif İşlek, Şerife Solmaz, and Kamran Hasanlı. 2020. “Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases With Osler-Weber- Rendu Syndrome”. European Journal of Rhinology and Allergy 3 (3): 69-71. https://doi.org/10.5152/ejra.2020.328.
EndNote
Eren E, Balcı MK, İşlek A, Solmaz Ş, Hasanlı K (December 1, 2020) Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases with Osler-Weber- Rendu Syndrome. European Journal of Rhinology and Allergy 3 3 69–71.
IEEE
[1]E. Eren, M. K. Balcı, A. İşlek, Ş. Solmaz, and K. Hasanlı, “Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases with Osler-Weber- Rendu Syndrome”, Eur J Rhinol Allergy, vol. 3, no. 3, pp. 69–71, Dec. 2020, doi: 10.5152/ejra.2020.328.
ISNAD
Eren, Erdem - Balcı, Mustafa Koray - İşlek, Akif - Solmaz, Şerife - Hasanlı, Kamran. “Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases With Osler-Weber- Rendu Syndrome”. European Journal of Rhinology and Allergy 3/3 (December 1, 2020): 69-71. https://doi.org/10.5152/ejra.2020.328.
JAMA
1.Eren E, Balcı MK, İşlek A, Solmaz Ş, Hasanlı K. Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases with Osler-Weber- Rendu Syndrome. Eur J Rhinol Allergy. 2020;3:69–71.
MLA
Eren, Erdem, et al. “Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases With Osler-Weber- Rendu Syndrome”. European Journal of Rhinology and Allergy, vol. 3, no. 3, Dec. 2020, pp. 69-71, doi:10.5152/ejra.2020.328.
Vancouver
1.Erdem Eren, Mustafa Koray Balcı, Akif İşlek, Şerife Solmaz, Kamran Hasanlı. Efficacy of High-Dose Bevacizumab Treatment in the Management of Epistaxis in Cases with Osler-Weber- Rendu Syndrome. Eur J Rhinol Allergy. 2020 Dec. 1;3(3):69-71. doi:10.5152/ejra.2020.328

You can find the current version of the Instructions to Authors at: https://www.eurjrhinol.org/en/instructions-to-authors-104

Starting on 2020, all content published in the journal is licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International
License which allows third parties to use the content for non-commercial purposes as long as they give credit to the original work. This license
allows for the content to be shared and adapted for non-commercial purposes, promoting the dissemination and use of the research published in
the journal.
The content published before 2020 was licensed under a traditional copyright, but the archive is still available for free access.